Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : MP1032
Therapeutic Area : Immunology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Long-term Toxicology Studies Confirm Very Good Safety Profile of MP1032
Details : The results confirm the very good safety profile of MetrioPharm's lead compound MP1032. They allow for long-term clinical studies in chronic indications to be conducted in the future.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 04, 2021
Lead Product(s) : MP1032
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : MP1032
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Syneos Health
Deal Size : Inapplicable
Deal Type : Inapplicable
MP1032 Treatment in Patients With Moderate to Severe COVID-19
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 21, 2021
Lead Product(s) : MP1032
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Syneos Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : MP1032
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Bioskin
Deal Size : Inapplicable
Deal Type : Inapplicable
Study to Evaluate Efficacy and Safety of MP1032 in Patients With Chronic Plaque Psoriasis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 15, 2018
Lead Product(s) : MP1032
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Bioskin
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : MP1032
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Parexel
Deal Size : Inapplicable
Deal Type : Inapplicable
Study to Evaluate Safety and Efficacy of Oral MP1032 in Psoriasis Patients
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 20, 2016
Lead Product(s) : MP1032
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Parexel
Deal Size : Inapplicable
Deal Type : Inapplicable